These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26999488)

  • 1. Use of Quantitative Dynamic Contrast-Enhanced Ultrasound to Assess Response to Antiangiogenic Therapy in Children and Adolescents With Solid Malignancies: A Pilot Study.
    McCarville MB; Coleman JL; Guo J; Li Y; Li X; Honnoll PJ; Davidoff AM; Navid F
    AJR Am J Roentgenol; 2016 May; 206(5):933-9. PubMed ID: 26999488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study.
    Lassau N; Bonastre J; Kind M; Vilgrain V; Lacroix J; Cuinet M; Taieb S; Aziza R; Sarran A; Labbe-Devilliers C; Gallix B; Lucidarme O; Ptak Y; Rocher L; Caquot LM; Chagnon S; Marion D; Luciani A; Feutray S; Uzan-Augui J; Coiffier B; Benastou B; Koscielny S
    Invest Radiol; 2014 Dec; 49(12):794-800. PubMed ID: 24991866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative contrast-enhanced ultrasound for imaging antiangiogenic treatment response in experimental osteolytic breast cancer bone metastases.
    Merz M; Komljenovic D; Semmler W; Bäuerle T
    Invest Radiol; 2012 Jul; 47(7):422-9. PubMed ID: 22659593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
    Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
    Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardization of dynamic contrast-enhanced ultrasound for the evaluation of antiangiogenic therapies: the French multicenter Support for Innovative and Expensive Techniques Study.
    Lassau N; Chapotot L; Benatsou B; Vilgrain V; Kind M; Lacroix J; Cuinet M; Taieb S; Aziza R; Sarran A; Labbe C; Gallix B; Lucidarme O; Ptak Y; Rocher L; Caquot LM; Chagnon S; Marion D; Luciani A; Uzan-Augui J; Koscielny S
    Invest Radiol; 2012 Dec; 47(12):711-6. PubMed ID: 23095862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging.
    Zhou J; Zhang H; Wang H; Lutz AM; El Kaffas A; Tian L; Hristov D; Willmann JK
    Angiogenesis; 2017 Nov; 20(4):547-555. PubMed ID: 28721500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy.
    Han KS; Jung DC; Choi HJ; Jeong MS; Cho KS; Joung JY; Seo HK; Lee KH; Chung J
    Cancer; 2010 May; 116(10):2332-42. PubMed ID: 20225226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of early response to antiangiogenic treatment with dynamic contrast enhanced ultrasound].
    Lassau N; Brule A; Chami L; Benatsou B; Péronneau P; Roche A
    J Radiol; 2008 May; 89(5 Pt 1):549-55. PubMed ID: 18535495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
    Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
    Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
    Interiano RB; McCarville MB; Wu J; Davidoff AM; Sandoval J; Navid F
    J Pediatr Surg; 2015 Sep; 50(9):1484-9. PubMed ID: 25783402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
    Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
    Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
    Akisik MF; Sandrasegaran K; Bu G; Lin C; Hutchins GD; Chiorean EG
    Radiology; 2010 Aug; 256(2):441-9. PubMed ID: 20515976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
    Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to anti-angiogenic treatment.
    Rix A; Lederle W; Siepmann M; Fokong S; Behrendt FF; Bzyl J; Grouls C; Kiessling F; Palmowski M
    Eur J Radiol; 2012 Oct; 81(10):2710-6. PubMed ID: 22093958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
    Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
    J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study.
    Wang J; Chen LT; Tsang YM; Liu TW; Shih TT
    AJR Am J Roentgenol; 2004 Sep; 183(3):713-9. PubMed ID: 15333360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of tumor microvascularity with respiratory gated contrast enhanced ultrasound for monitoring therapy.
    Averkiou M; Lampaskis M; Kyriakopoulou K; Skarlos D; Klouvas G; Strouthos C; Leen E
    Ultrasound Med Biol; 2010 Jan; 36(1):68-77. PubMed ID: 19900749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Color-coded perfusion analysis of CEUS for pre-interventional diagnosis of microvascularisation in cases of vascular malformations.
    Teusch VI; Wohlgemuth WA; Piehler AP; Jung EM
    Clin Hemorheol Microcirc; 2014; 58(1):183-93. PubMed ID: 25227194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US.
    McCarville MB; Streck CJ; Dickson PV; Li CS; Nathwani AC; Davidoff AM
    Radiology; 2006 Jul; 240(1):73-81. PubMed ID: 16793972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regions of interest and parameters for the quantitative analysis of contrast-enhanced ultrasound to evaluate the anti-angiogenic effects of bevacizumab.
    Zhang HP; Shi QS; Li F; Liu L; Bai M; Gu JY; Wu Y; Du LF
    Mol Med Rep; 2013 Jul; 8(1):154-60. PubMed ID: 23722237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.